Herbal Treatment to Improve Chemotherapy Delivery

Inclusion Criteria:

* Patient with pathological diagnosis of colon cancer; no residual tumor at the resection margin.
* tumor-node-metastasis(TNM)Stage II (high-risk)or III colon cancer according to 8th edition of American Joint Committee on Cancer(AJCC)Staging Manual. High-risk stage II disease is characterized by at least one of the following:

  1. T4 tumor,
  2. inadequately sampled nodes (\<12 lymph nodes),
  3. clinical presentation with bowel obstruction or perforation,
  4. poorly differentiated histology ,exclusive of those cancers that are High degree of microsatellite instability(MSI-H),
  5. lymphovascular invasion,perineural invasion(PNI).
* Underwent radical surgery no more than six weeks ago and plan to start chemotherapy.
* Have not been enrolled in other therapeutic clinical trials within the near 30 days.
* Age between 18 to 75 years; All genders; Eastern Cooperative Oncology Group - performance status(ECOG-PS)from 0 to 2; Women who are pregnant, lactating or of reproductive age are not eligible, while those of reproductive age using secure contraceptives are eligible.
* No history of previous malignancy other than adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell carcinoma of the skin, unless there has been a disease-free interval of at least 5 years.
* Laboratory testing: blood routine examination: WBC≥3.5×109/L，NEUT≥1.5×109/L,PLT≥100×109/L,HGB≥90g/L;biochemical tests:TBIL≤1.5×ULN,AST(SGOT),ALT(SGPT)≤2.5×ULN,Scr≤1.5×ULN;CEA after surgery was normal.
* Consented.
* Agree not to be enrolled in other interventional studies during the research.

Exclusion Criteria:

* Patients not suitable for chemotherapy of CapeOX ,which will be determined by the investigator or the attending physician.
* Clinically relevant cardiovascular and/or cerebrovascular disease,active hepatitis,severe abnormalities in liver/ renal function tests.
* Known allergy to any of the components of study drug.
* Those who cannot take the study drug orally because of bowel obstruction and/or require for peripheral vein nutrition.
* Malabsorption or diseases that affect the absorption.
* Unstable situations or situations that may endanger the safety of patients and their compliance, such as severe mental illness,schizophrenia.
* Colostomy